MedWatch

FDA includes CV benefits of Novo’s Victoza in label

The ability to reduce the risk of major cardiovascular events is now included in the US label for Novo Nordisk’s diabetes drug Victoza, giving the pharma company a “great competitive edge”, according to one analyst.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

Lægemiddelstyrelsen er skuffet, men glad for bronzen

Lægemiddelstyrelsens direktør Thomas Senderovitz er skuffet over, at København ikke skal huse EMA, men også stolt over at have snuppet "bronzemedaljerne". Han påpeger dog også, at der ligger masser af arbejde forude i forbindelse med flytningen af lægemiddelagenturet.

Latest Top picks in English

Related articles